首页>
外国专利>
USE OF LONG-ACTING HUMAN RECOMBINANT SOLUBLE TUMOR NECROSIS FACTOR A RECEPTOR IN THE PREPARATION OF DRUGS FOR PREVENTING AND TREATING SEVERE LIVER INJURY ON CHRONIC LIVER DISEASE
USE OF LONG-ACTING HUMAN RECOMBINANT SOLUBLE TUMOR NECROSIS FACTOR A RECEPTOR IN THE PREPARATION OF DRUGS FOR PREVENTING AND TREATING SEVERE LIVER INJURY ON CHRONIC LIVER DISEASE
展开▼
机译:长效人类重组可溶性肿瘤坏死因子受体在制备药物中的用途:预防和治疗对慢性肝病的严重肝损伤
展开▼
页面导航
摘要
著录项
相似文献
摘要
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (HusTNFR) and belongs to the gene engineering technology and gene function application field. This invention uses type I or type II long-acting HusTNFR (LHusTNFR) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models. The results showed that LHusTNFR, which has a half-life of 12-140 hours, shows excellent efficacy for preventing the development of severe liver injury on chronic liver disease and for treating early-stage severe liver injury on chronic liver disease. It also significantly reduced the mortality of the model animals. Its efficacy for the prevention and treatment of early-stage severe liver injury on chronic liver disease was significantly better than that of non-LHusTNFR.
展开▼